King Pharmaceuticals, Inc. http://www.alacrastore.com/company-snapshot/King_Pharmaceuticals_Inc-2003011 09 Nov 2009 12:47:35 EST 2003011 King Pharmaceuticals, Inc. en AlacraStore RSS Builder 1.0 30 http://www.alacrastore.com/storecontent/ccbn/B2524019B2524019ccbn/B2524019norm05 Nov 2009 01:07:00 EST2524019Edited Brief of KG earnings conference call or presentation, 5-Nov-09 11:00am ETKing Pharmaceuticals106.0000EditedKing Pharmaceuticals Q3 2009 Earnings Conference Call SummaryKG11:00am ETBrief...Jack Howarth King Pharmaceuticals - VP, IR Brian Markison King Pharmaceuticals - Chairman, President, CEO Eric Carter King Pharmaceuticals - Chief Science Officer Steve Andrzejewski King Pharmaceuticals - Chief Commercial Officer... Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/T2524019T2524019ccbn/T2524019norm05 Nov 2009 12:09:00 EST2524019Final Transcript of KG earnings conference call or presentation, 5-Nov-09 11:00am ETKing Pharmaceuticals106.0000FinalKing Pharmaceuticals Q3 2009 Earnings Conference Call TranscriptKG11:00am ETTranscript...Jack Howarth King Pharmaceuticals - VP, IR Brian Markison King Pharmaceuticals - Chairman, President, CEO Eric Carter King Pharmaceuticals - Chief Science Officer Steve Andrzejewski King Pharmaceuticals - Chief Commercial Officer... Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/newstex/BW-0001-39453345BW-0001-39453345newstex/BW-0001-39453345xmlNewstex Inc.2005King Pharmaceuticals, Inc.Newstex Inc.newstex.comnewstexBW-0001-39453345Business Wire0001Business WireBW1Newstex Inc.Business Wire0800000008007000110000001100600011006006040000000401600004016048040160180401600104016005040160030400200004002006040100000401000107000000070140000701401213000000130100001301000505 Nov 2009 08:18:06 EST180000001800400018008000180160001802000011/5/2009 Nov. #, #### (Business Wire) -- King Pharmaceuticals, Inc. (NYSE:KG) announced today that total revenues were $### million during the third quarter ended September ##, ####, compared to $### million in the third quarter of ####. The...KING PHARMACEUTICALS INCBRIAN A MARKISONJOSEPH SQUICCIARINOKGNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/BW-0001-39252547BW-0001-39252547newstex/BW-0001-39252547xmlNewstex Inc.2005King Pharmaceuticals, Inc.Newstex Inc.newstex.comnewstexBW-0001-39252547Business Wire0001Business WireBW1Newstex Inc.Business Wire080000000800700004000000040020000400200604016000040160180401604804016001110000001100600011006006070000000701400007014012070030000700300113000000130100001301000529 Oct 2009 08:23:40 EST18000000180040001800800010/29/2009 Oct. ##, #### (Business Wire) -- King Pharmaceuticals, Inc. (NYSE:KG) announced today that the Company plans to report financial results for the third quarter ended September ##, #### prior to the market open on Thursday, November...KING PHARMACEUTICALS INCKGNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/BW-0001-39189736BW-0001-39189736newstex/BW-0001-39189736xmlNewstex Inc.2005King Pharmaceuticals, Inc.Newstex Inc.newstex.comnewstexBW-0001-39189736Business Wire0001Business WireBW1Newstex Inc.Business Wire0700000007010000080000000800700004000000040020000400200604016000040160310401600507014000070140120700300007003001110000001100600011006006130000001301000013010005130010001300100227 Oct 2009 12:27:28 EST18000000180160001802000019000000190010001900200710/27/2009 Oct. ##, #### (Business Wire) -- King Pharmaceuticals, Inc. (NYSE:KG) announced today that it has licensed from Merck Sante S.A.S., an affiliate of Merck KGaA, Darmstadt, Germany, the exclusive rights to market and sell CYANOKIT ®...KING PHARMACEUTICALS INCMERCK & CO INCMERCK KGAABRIAN A MARKISONKGMKGAYMRKNewsNewstexhttp://www.alacrastore.com/storecontent/ccbn/T2447460T2447460ccbn/T2447460norm22 Sep 2009 12:05:00 EST2447460Final Transcript of KG presentation, 22-Sep-09 11:00am ETKing Pharmaceuticals54.0000FinalKing Pharmaceuticals at UBS Global Life Sciences Conference TranscriptKG11:00am ETTranscript...Unidentified Participant Okay. So the next presentation is going to be King Pharmaceuticals and with us from King is, we have Brian Markinson, who is the CEO. We have Joe Squicciarino, who is the CFO. And we have Jack Howarth who runs IR. Jack is going to run through the presentation and then everyone is going to be available for the Q&A session. So thank you very much and I will turn it over to you, Jack. Jack Howarth - King Pharmaceuticals, Inc. - IR Thanks, Mark. Good morning, everybody. I appreciate the opportunity to share with you an overview of the Company and some opportunities for long-term growth and upcoming milestones. Before continuing, I should note that the presentation will include forward-looking statements which are discussed in the risk factors section and other sections of the Company's current Form ##-K for the year ended December ##, ####, and Form ##-Q for the quarter ended June ##, ####, which are on file with the US Securities and Exchange Commission. King Pharmaceuticals... Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/newstex/MW-0001-37908898MW-0001-37908898newstex/MW-0001-37908898xmlNewstex Inc.2005Copyright (c) 2009, Marketwire. All rights reserved. All the news releases provided by Market Wire are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited.AgraQuestDAVIS, CA and BRIDGEWATER, NJNewstex Inc.newstex.comnewstexMW-0001-37908898Marketwire0001MarketwireMW1Newstex Inc.Marketwire040000000400100004001001040100000401000107000000070140000701401213000000130100001301000511 Sep 2009 06:18:18 EST1800000018020000180160009/11/2009 DAVIS, CA and BRIDGEWATER, NJ, Sep. ##, #### (Marketwire delivered by Newstex) -- DAVIS, CA and BRIDGEWATER, NJ -- (Marketwire) -- ##/##/## -- AgraQuest Inc. and Alpharma Animal Health announced today that they have agreed to terms...KING PHARMACEUTICALS INCKGNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/BW-0001-37718122BW-0001-37718122newstex/BW-0001-37718122xmlNewstex Inc.2005King Pharmaceuticals, Inc.Newstex Inc.newstex.comnewstexBW-0001-37718122Business Wire0001Business WireBW1Newstex Inc.Business Wire0700000007013000080000000800700004000000040020000400200604016000040160010701400007014012070030000700300111000000110060001100600613000000130100001301000503 Sep 2009 06:24:02 EST18000000180160001802000019000000190010009/3/2009 Sep. #, #### (Business Wire) -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) and King Pharmaceuticals, Inc. (NYSE: KG) announced today that they met with the U.S. Food and Drug Administration ("FDA") on September #, #### to discuss the...ACURA PHARMACEUTICALS, INCKING PHARMACEUTICALS INCACURKGNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/BW-0001-37240818BW-0001-37240818newstex/BW-0001-37240818xmlNewstex Inc.2005Zacks.comNewstex Inc.newstex.comnewstexBW-0001-37240818Business Wire0001Business WireBW1Newstex Inc.Business Wire080000000800700004000000040160000401604804016001040160180400200004002006110000001100600011006006070000000700300007003001070140000701401214 Aug 2009 06:21:54 EST1800000018008000180040008/14/2009 Aug. ##, #### (Business Wire) -- Zacks Equity Research highlights Gafisa S.A. (NYSE: GFA ) as the Bull of the Day and King Pharmaceuticals (NYSE: KG ) the Bear of the Day. In addition, Zacks Equity Research provides analysis on Bally...GAFISA S.A.INTERNATIONAL GAME TECHNOLOGYKING PHARMACEUTICALS INCWMS INDUSTRIES INCGFAIGTKGWMSNewsNewstexhttp://www.alacrastore.com/research/s-and-p-credit-research-Summary_King_Pharmaceuticals_Inc-739274739274spcred/739274normglobal12 Aug 2009 02:45:08 EST175SummaryThe latest Summary from S&PUnited StatesPharmaceuticalsUnited StatesGlobal IssuersSummaryUSA49558249558P35202010 352020 3520 35King Pharmaceuticals Inc.330208USAKGSUMMARYConsumerCORPGLOBISSHealthLEVFINCredit & Investment ResearchS&P Credit Researchhttp://www.alacrastore.com/research/s-and-p-credit-research-King_Pharmaceuticals_Inc-739122739122spcred/739122normglobal10 Aug 2009 06:23:00 EST400Full ReportThe latest Full Report from S&PUnited StatesPharmaceuticalsUnited StatesGlobal IssuersFull ReportUSA49558249558P35202010 352020 3520 35King Pharmaceuticals Inc.330208USAKGFULLConsumerCORPGLOBISSHealthLEVFINCredit & Investment ResearchS&P Credit Researchhttp://www.alacrastore.com/storecontent/ccbn/B2364918B2364918ccbn/B2364918norm06 Aug 2009 02:07:00 EST2364918Edited Brief of KG earnings conference call or presentation, 6-Aug-09 11:00am ETKing Pharmaceuticals54.0000EditedKing Pharmaceuticals Q2 2009 Earnings Conference Call SummaryKG11:00am ETBrief...Jack Howarth King Pharmaceuticals - VP, IR Brian Markison King Pharmaceuticals - Chairman, President, CEO Joe Squicciarino King Pharmaceuticals - CFO Steve Andrzejewski King Pharmaceuticals - Chief Commercial Officer CONFERENCE CALL PARTICIPANTS... Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/T2364918T2364918ccbn/T2364918norm06 Aug 2009 01:09:00 EST2364918Final Transcript of KG earnings conference call or presentation, 6-Aug-09 11:00am ETKing Pharmaceuticals54.0000FinalKing Pharmaceuticals Q2 2009 Earnings Conference Call TranscriptKG11:00am ETTranscript...Jack Howarth King Pharmaceuticals - VP, IR Brian Markison King Pharmaceuticals - Chairman, President, CEO Joe Squicciarino King Pharmaceuticals - CFO Steve Andrzejewski King Pharmaceuticals - Chief Commercial Officer C O N F E R E N C E C A L L P A R T I C I P A N T S... Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/bir/565601565601bir/565601norm17King Pharmaceuticals Inc.Medco Research Inc.Jones Pharma Inc.Meridian Medical Technologies Inc.Alpharma Inc.A.L. Labretories Inc.Cox PharmaceuticalsSIGAA L PharmaAlpharma Operating corp.Alpharma Inc. Animal Health Div.United States27 May 2009 06:19:00 ESTKing Pharmaceuticals Inc. researches and develops, manufactures, markets and sells branded prescription pharmaceutical products and animal health products. The company has four main segments--a specialty-driven branded prescription pharmaceuticals businesNYSE325412K2834GKGKing Pharmaceuticals Inc. researches and develops, manufactures, markets and sells branded prescription pharmaceutical products and animal health products. The company has four main segments--a specialty-driven branded prescription pharmaceuticals businesCompany Profiles & FinancialsGale Company Profileshttp://www.alacrastore.com/storecontent/ccbn/T2210248T2210248ccbn/T2210248norm12 May 2009 05:06:00 EST2210248Final Transcript of KG presentation, 12-May-09 2:00pm ETKing Pharmaceuticals54.0000FinalKing Pharmaceuticals at Bank of America Securities Healthcare Conference TranscriptKG2:00pm ETTranscript...David Robinson King Pharmaceuticals - VP-IR Brian Markison King Pharmaceuticals - CEO Joe Squicciarino King Pharmaceuticals - CFO P R E S E N T A T I O N... Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/B2187473B2187473ccbn/B2187473norm11 May 2009 04:07:00 EST2187473Edited Brief of KG earnings conference call or presentation, 11-May-09 1:00pm ETKing Pharmaceuticals54.0000EditedKing Pharmaceuticals Q1 2009 Earnings Conference Call SummaryKG1:00pm ETBrief...David Robinson King Pharmaceuticals - VP, IR Brian Markison King Pharmaceuticals - Chairman, President, CEO Joe Squicciarino King Pharmaceuticals - CFO Steve Andrzejewski King Pharmaceuticals - Chief Commerical Officer CONFERENCE CALL PARTICIPANTS... Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/T2187473T2187473ccbn/T2187473norm11 May 2009 03:07:00 EST2187473Final Transcript of KG earnings conference call or presentation, 11-May-09 1:00pm ETKing Pharmaceuticals54.0000FinalKing Pharmaceuticals Q1 2009 Earnings Conference Call TranscriptKG1:00pm ETTranscript...David Robinson King Pharmaceuticals - VP, IR Brian Markison King Pharmaceuticals - Chairman, President, CEO Joe Squicciarino King Pharmaceuticals - CFO Steve Andrzejewski King Pharmaceuticals - Chief Commerical Officer C O N F E R E N C E C A L L P A R T I C I P A N T S... Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/T2110815ccbn/T2110815normT2110815... - King Pharmaceuticals - Vice President-Investor Relations Good afternoon, ladies and gentlemen. I'm David Robinson, Vice President-Investor Relations with King Pharmaceuticals, and thanks for joining us today. Today we're going to share with you an overview of our Company, recent events, and opportunities for long-term growth. Before continuing, you should note that this presentation will include forward-looking statements. Forward-looking statements reflect management's current view of future events and operations, and include but are not limited to statements pertaining to the Company's strategic plan for growth, development pipeline, and certain financial expectations. Forward-looking statements involve risks and uncertainties. Certain factors that may cause actual results to differ materially from the forward-looking statements are discussed in the Risk Factors section and other sections of the Company's current Form ##-K for the year ended December ##, ####, which is on file with... 16 Mar 2009 08:06:00 ESTKing Pharmaceuticals54.0000FinalKing Pharmaceuticals at Cowen and Company Healthcare Conference TranscriptKG4:40pm ETTranscriptCredit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/B2106286ccbn/B2106286normB2106286...Substantial and indicative of continued aggressive execution of strategy for long-term growth initiated few years ago. ... 26 Feb 2009 02:07:00 ESTKing Pharmaceuticals54.0000EditedKing Pharmaceuticals Q4 2008 Earnings Conference Call SummaryKG11:00am ETBriefCredit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/T2106286ccbn/T2106286normT2106286...Good morning, thank you for joining today's King Pharmaceuticals' fourth quarter #### financial results. Please welcome James Green, Executive Vice President of Corporate Affairs of King Pharmaceuticals. ... 26 Feb 2009 12:07:00 ESTKing Pharmaceuticals54.0000FinalKing Pharmaceuticals Q4 2008 Earnings Conference Call TranscriptKG11:00am ETTranscriptCredit & Investment ResearchThomson StreetEvents